Business Wire

THE-NATURE-CONSERVANCY

22.4.2024 08:01:25 CEST | Business Wire | Press release

Share
The Government of Mongolia and The Nature Conservancy Secure ‘Eternal Mongolia’, a Pathway to Achieve the Nation’s Climate and Biodiversity Goals

Today, the Government of Mongolia, The Nature Conservancy (TNC), and others announced the launch of Eternal Mongolia – a Project Finance for Permanence (PFP) initiative that will deliver lasting conservation and sustainable community development for the Central Asian country whose vast steppe represents our planet’s last great tract of intact temperate grassland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240421544883/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mongolia's Nationally Protected area, Toson Hulstai. ©TNC

Eternal Mongolia is a negotiated partnership that will deliver USD $198 million of new investment over 15 years to support Mongolia’s ambitious goals and deliver lasting conservation and sustainable community development in and around protected areas. This includes a USD $71 million transition fund from private and other global donor sources. This transition fund will accelerate Mongolia’s conservation and community development goals, while providing time to develop sustainable financing mechanisms to ensure protected areas can be managed sustainably in the long-term and that Mongolian people benefit from nature, now and for the future.

Eternal Mongolia will dramatically expand and strengthen the effectiveness of the country’s entire National Protected Area network, support sustainable herding practices, invest in the sustainable tourism industry, and set an unprecedented example to the rest of the world about the value of land and freshwater conservation.

The PFP will support local community-driven proposals to safeguard an additional 14.4 million hectares of Mongolia’s lands and waters including intact grasslands, forests, deserts, wetlands and rivers; strengthen the management of all of Mongolia’s National Protected Areas covering 47 million hectares; and extend sustainable and climate-resilient community-managed practices to 34 million hectares outside protected areas.

Mongolia established itself as a world conservation leader 30 years ago by committing to a vision revolutionary for its time: to protect 30% of its lands—a goal now shared around the world. Eternal Mongolia unlocks all the funding and policy commitments needed for Mongolia to ensure its 30% conservation target will be met by 2030 while providing a secure and economic future for Mongolians.

Eternal Mongolia is an initiative of Enduring Earth, an ambitious collaboration between The Nature Conservancy, The Pew Charitable Trusts, World Wildlife Fund (WWF) and ZOMALAB that works in partnership with nations and communities as they accelerate and amplify conservation for a more sustainable, prosperous future for people and planet.

“To address the dual climate and biodiversity crises we must catalyze action at scale and ensure that people and livelihoods are at the center of the solution,” said Jennifer Morris, CEO of The Nature Conservancy and Board Chair of Enduring Earth.

Eternal Mongolia anticipates key financial support from Legacy Landscapes Fund. Eternal Mongolia initiatives would not be possible without philanthropic support from Jennifer Speers, Pamela Tanner Boll, The Jeremy and Hannelore Grantham Environmental Trust, Joanna & Stuart Brown, The Lorinet Foundation, China Global Conservation Fund, Sabra Turnbull & Clifford Burnstein, Trafigura Foundation, Margaret A. Cargill Philanthropies, Arcadia, Fondation Hans Wilsdorf, The Gallogly Family Foundation, and Robert W. Wilson Charitable Trust.

The full version of this press release with more information and additional quotes, including those from the Government of Mongolia, can be found at www.nature.org/en-us/newsroom/eternal-mongolia-pfp-announcement/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240421544883/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye